Clinical Trial Update: First-in-Human Single and Multiple Dose of HL-400 [Phase 1]

View source ↗

Summary

Update on a first-in-human Phase 1 trial of HL-400 for Parkinson disease. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• HL-400

Snippet

Sponsor: Highlightll Pharmaceutical (USA) LLC | Conditions: Parkinson Disease | Phase 1 | Status: RECRUITING